Back
Akebia Therapeutics Quote, Financials, Valuation and Earnings
The Mysterious VC Firm Behind Nvidia's Secret Weapon
Details Here!
Buy
68
AKBA
Akebia Therapeutics
Last Price:
1.96
Seasonality Move:
44.29%
7 Day Trial
ALL ACCESS PASS
$
7
Trump's IRS Hands Massive 'Victory Gift' To 401K Owners
Shield your IRA, 401(k) and pension savings from this coming anti-Trump backlash.Akebia Therapeutics Price Quote
$1.96
-0.03 (-1.51%)
(Updated: November 12, 2024 at 5:55 PM ET)
Akebia Therapeutics Key Stats
Buy
68
Akebia Therapeutics (AKBA)
is a Buy
Day range:
$1.90 - $2.02
52-week range:
$0.80 - $2.48
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.26
P/B ratio:
0%
Volume:
2.9M
Avg. volume:
2.1M
1-year change:
122.84%
Market cap:
$418.5M
Revenue:
$194.6M
EPS:
$-0.21
How Much Does Akebia Therapeutics Make?
-
How Much Are Akebia Therapeutics's Sales Annually?
AKBA Revenues are $194.6M -
How Much Profit Does Akebia Therapeutics's Make A Year?
AKBA net income is -$51.9M
Is Akebia Therapeutics Growing As A Company?
-
What Is Akebia Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.23% -
What Is Akebia Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Akebia Therapeutics Stock Price Performance
-
Did Akebia Therapeutics Stock Go Up Last Month?
Akebia Therapeutics share price went up by 50.76% last month -
Did AKBA's Share Price Rise Over The Last Year?
AKBA share price rose by 122.84% over the past 1 year
What Is Akebia Therapeutics 52-Week High & Low?
-
What Is Akebia Therapeutics’s 52-Week High Share Price?
Akebia Therapeutics has traded as high as $2.48 over the past 52 weeks -
What Is Akebia Therapeutics’s 52-Week Low Share Price?
Akebia Therapeutics has traded as low as $0.80 over the past 52 weeks
Akebia Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Akebia Therapeutics?
-
How Much Debt Does Akebia Therapeutics Have?
Total long term debt quarterly is $38M -
How Much Cash Does Akebia Therapeutics Have?
Cash and short term investments quarterly total is $39.5M -
What Is Akebia Therapeutics’s Book Value Per Share?
Book value per share is -0.16
Is Akebia Therapeutics Cash Flow Positive?
-
What Is AKBA Cash Flow From Operations?
Cash flow from operations (TTM) is -$39M -
What Is Akebia Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $24.9M -
What Is Akebia Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$29K
Akebia Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
AKBA return on invested capital is -671.06% -
What Is Akebia Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -17.19% -
What Is AKBA Return On Equity?
ROE is a measure of profitability and is 0%
Akebia Therapeutics Earnings Date & Stock Price
-
What Is Akebia Therapeutics's Stock Price Today?
A single share of AKBA can be purchased today for 1.99 -
What Is Akebia Therapeutics’s Stock Symbol?
Akebia Therapeutics trades on the nasdaq under the ticker symbol: AKBA -
When Is Akebia Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Akebia Therapeutics is scheduled on March 14, 2025 -
When Is AKBA's next ex-dividend date?
Akebia Therapeutics's next ex-dividend date is November 13, 2024 -
How To Buy Akebia Therapeutics Stock?
You can buy Akebia Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Akebia Therapeutics Competitors
-
Who Are Akebia Therapeutics's Competitors?
Below is a list of companies who compete with Akebia Therapeutics or are related in some way:
Akebia Therapeutics Dividend Yield
-
What Is AKBA Dividend Yield?
Akebia Therapeutics’s dividend yield currently is 0% -
What Is Akebia Therapeutics’s Payout Ratio?
Akebia Therapeutics’s payout ratio is 0% -
When Did Akebia Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 13, 2024 -
What Is Akebia Therapeutics’s Dividend Per Share?
Akebia Therapeutics pays a dividend of $0.00 per share
Akebia Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -100% |
| Revenue: | -22.58% | -15.9% |
Analyst Recommendations
| Buy Recommendations: | 1 |
|---|---|
| Hold Recommendations: | 0 |
| Sell Recommendations: | 0 |
| Price Target: | 5.50 |
| Upside from Last Price: | 176.38% |